Novel imidazo [4,5-C] quinoline and imidazo [4,5-C][1,5] naphthyridine derivatives as LRRK2 inhibitors

The present invention provides novel imidazo[4,5-c]quinoline and imidazo[4,5-c][1,5]naphthyridine derivatives of Formula (I), and the pharmaceutically 5 acceptable salts thereof Rib R2 R a wherein R 1, R 1a, R1b, R2, R4, R5, R6, X and Z are as defined in the specification. The invention is also dire...

Full description

Saved in:
Bibliographic Details
Main Authors Verhoest, Patrick Robert, Reesf, Matthew Richard, Stepan, Antonia Friederike, Wager, Travis T, Garnsey, Michelle Renee, Henderson, Jaclyn Louise, Kormos, Bethany Lyn, Kurumbail, Ravi G, Galatsis, Paul, Pettersson, Martin Youngjin
Format Patent
LanguageEnglish
Published 08.04.2021
Subjects
CHEMISTRY
HETEROCYCLIC COMPOUNDS
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online AccessGet full text

Cover

More Information
Summary:The present invention provides novel imidazo[4,5-c]quinoline and imidazo[4,5-c][1,5]naphthyridine derivatives of Formula (I), and the pharmaceutically 5 acceptable salts thereof Rib R2 R a wherein R 1, R 1a, R1b, R2, R4, R5, R6, X and Z are as defined in the specification. The invention is also directed to pharmaceutical compositions comprising the 0 compounds of Formula (I) and to use of the compounds in the treatment of diseases associated with LRRK2, such as neurodegenerative diseases including Parkinson's disease or Alzheimer's disease, cancer, Crohn's disease or leprosy.
Bibliography:Application Number: AU20210201608